As a treatment for leukemia, the drug was already approved by the American regulator in 2017. (The number of offers should remain)
By the end of the year, clinical trials will begin in Denmark for a drug that could prove to be a long-awaited treatment for the human immunodeficiency virus (HIV). The results of preliminary laboratory experiments conducted by two teams of Australian scientists in collaboration with colleagues from Denmark give cause for cautious optimism. The article describing the results of the “check” has been published in the journal Cell Reports Medicine.
A study by Australians convincingly demonstrates that the oncology drug venetoclax is able to detect and destroy “dormant cells” in our body that are infected with a deadly virus. The following year, trials of the drug begin in Melbourne, Australia, in addition to Denmark. At the same time, the tablets under the trade name VENCLEXTA were originally developed to treat leukemia, an aggressive form of blood cancer. It was approved in the U.S. in 2016 and has since helped thousands of oncology patients, according to doctors.
The main developer of the drug is the Swiss company Roche. There are currently nearly 40 million people living with HIV in the world. Timely diagnosis of the infection and prompt initiation of antiretroviral therapy can stop the virus from replicating and thus stop the destruction of the immune system. If the infected person takes the pills regularly, he or she will no longer be a threat to those close to him or her, but will not be cured. It is worthwhile to stop taking the prescribed medication every day – and the disease will return.